Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM512 in moderate-to-severe asthma
NCT07011524Phase 2Recruiting
- Sponsor
- Keymed Biosciences
- Start
- Aug 2025
- Primary completion
- Jul 2027
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing CM512 Arm with Placebo Arm (2 arms). Primary endpoint: Change from the baseline in Forced Expiratory Volume in one second at 12 weeks. Started Aug 2025; status: recruiting.
02
Drugs
CM512
03
Conditions
asthma
Beyond the preview
Go deeper on NCT07011524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07011524.